Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASCO 2025
Biotech
To Gilead's new CMO, pipeline diversification is key
Gilead's CMO said he’s trying to build a “balanced” and “partially derisked portfolio” by combining direct cytotoxic mechanisms with immuno-oncology.
Angus Liu
Jun 9, 2025 10:00am
As investors pivot from cell therapy, Immatics keeps the faith
Jun 6, 2025 3:50am
Are Lilly, Novartis eyeing the PD-1xVEGF field? Execs weigh in
Jun 4, 2025 1:00pm
Guardant360-guided breast cancer therapy swaps boost survival
Jun 3, 2025 10:00am
OSE shares 65% OS rate behind cancer vaccine's phase 2 win
Jun 3, 2025 7:05am
ASCO: Kura, Kyowa reveal 23% remission rate behind leukemia win
Jun 2, 2025 5:36pm
